NCT02200042终止3 期
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- NRG Oncology
- 入组人数
- 1
- 试验地点
- 54
- 主要终点
- Overall Survival
研究概览
简要总结
This randomized phase III trial studies how well gemcitabine hydrochloride and cisplatin with or without radiation therapy work in treating patients with localized liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x rays to kill tumor cells. It is not yet known whether giving gemcitabine and cisplatin is more effective with or without radiation therapy in this patient population. Patients register to this study after receiving gemcitabine and cisplatin.
详细描述
PRIMARY OBJECTIVES:
I. To evaluate the addition of liver-directed radiation therapy with respect to overall survival (OS) for patients with unresectable, localized intrahepatic cholangiocarcinoma.
SECONDARY OBJECTIVES:
I. To evaluate the addition of liver-directed radiation therapy with respect to local control for patients with unresectable, localized intrahepatic cholangiocarcinoma.
II. To evaluate the addition of liver-directed radiation therapy with respect to adverse events for patients with unresectable, localized intrahepatic cholangiocarcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically (histologically or cytologically) proven diagnosis of intrahepatic cholangiocarcinoma (IHC) without distant extrahepatic metastasis prior to study entry. Patients with an adenocarcinoma suggestive of a pancreaticobiliary primary with radiographic findings consistent with an intrahepatic cholangio-carcinoma are eligible.
- •Patient must have 1 lesion with a maximum AXIAL diameter of 12cm at the time of study entry. Up to 3 satellite lesions are permitted. Satellite lesions, are defined as lesions less than 2 cm that are within 1 cm of the periphery of the dominant lesion (gross tumor volume [GTV]) are permitted. The satellite lesions are NOT included in the AXIAL diameter measurement. Regional Lymph Node involvement within the porta hepatis (as medial as superior mesenteric vein [SMV] portal vein confluence) is permitted if nodes are deemed clinically positive (i.e. FDG [Fluorine 18 fluorodeoxyglucose] avid);
- •Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:
- •Pre-study entry Scan (REQUIRED for All Patients to confirm no progression): computed tomography (CT) scan chest/abdomen/pelvis with multiphasic liver CT scan within 30 days prior to study entry. If CT contrast is contraindicated, CT chest without contrast and MRI of abdomen and pelvis is permitted;
- •Zubrod Performance Status 0-1 at the time of study entry;
- •Complete blood count (CBC) / differential obtained within 21 days prior to study entry, with adequate bone marrow function defined as follows:
- •Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3;
- •Platelets ≥ 75,000 cells/mm3;
- •Total bilirubin < 2.5 mg/dl;
- •Aspartate Aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (Serum glutamic pyruvic transaminase [SGPT]) < 5.0 X institutional upper limit of normal;
- •Albumin ≥ 2.5mg/dl;
- •Creatinine within normal institutional limits or creatinine clearance ≥ 60 mL/min/1.73 m2 for subject with creatinine levels above institutional normal;
- •Hemoglobin(Hgb) ≥ 9.0 g/dl. (Note: The use of transfusion or other intervention to achieve Hgb ≥ 9.0 g/dl is acceptable.)
- •Patient must provide study specific informed consent prior to study entry;
- •Negative Beta-Human Chorionic Gonadotropin (bHCG) prior to study entry if patient is pre or peri-menopausal.
- •Must have received 6 months of Gemcitabine/Cisplatin chemotherapy without progression. Disease response to chemotherapy is also permitted. If toxicity precludes 6 months of chemotherapy at least 4 months of Gemcitabine/Cisplatin must have been administered.
排除标准
- •Multiple lesions that don't meet the criteria as satellite lesions as defined in protocol;
- •Extrahepatic metastases or malignant nodes beyond the periportal region. Celiac, pancreaticoduodenal and para-aortic nodes> 2 cm are ineligible. Note that benign non-enhancing periportal lymphadenopathy is not unusual in the presence of hepatitis and is permitted, even if the sum of enlarged nodes is > 2.0 cm;
- •Hepatic insufficiency resulting in clinical jaundice, encephalopathy and/or variceal bleed at the time of study entry;
- •Prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields;
- •Prior selective internal radiotherapy/hepatic arterial Yttrium therapy, at any time;
- •Direct tumor extension into the stomach, duodenum, small bowel or large bowel;
- •Prior invasive malignancy, excluding the current diagnosis, (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years. (Note: carcinoma in situ of the breast, oral cavity, or cervix is all permissible);
- •Prior systemic chemotherapy for the study cancer other than gemcitabine/cisplatin; note that prior chemotherapy for a different cancer is allowable;
- •Currently receiving other anti-cancer agents;
- •Participants who require anticoagulation should receive low-molecular weight or standard heparin and not warfarin;
- •Prior surgery for the IHC. (Liver resection is not allowed);
- •Severe, active co-morbidity, defined as follows:
- •Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months of study entry;
- •Transmural myocardial infarction within the last 6 months of study entry;
- •Acute bacterial or fungal infection requiring intravenous antibiotics at the time of study entry;
- •Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to study entry;
- •HIV positive with CD4 (cluster of differentiation 4) count < 200 cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter at the time of study entry. Note also that HIV testing is not required for eligibility for this protocol;
- •End-stage renal disease (ie, on dialysis or dialysis has been recommended).
- •Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic;
- •Grade 3 or higher peripheral neuropathy at the time of study entry.
研究组 & 干预措施
Observation
No Intervention
No radiation therapy
Radiation therapy
Experimental
Liver-directed radiation therapy
干预措施: Image Guided Radiation Therapy (Radiation)
结局指标
主要结局
Overall Survival
时间窗: From randomization to last follow-up. Analysis occurs after all patients have been on study for at least two years.
Overall survival time is defined as time from randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact.
次要结局
- Incidence of Adverse Events Evaluated Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0(From randomization to last follow-up. Analysis occurs after all patients have been on study for at least two years.)
- Progression-free Survival (PFS)(From randomization to last follow-up. Analysis occurs after all patients have been on study for at least two years.)
- Regional Progression Defined as Progression or Existing or Appearance of New Nodal Disease(From randomization to last follow-up. Analysis occurs after all patients have been on study for at least two years.)
- Distant Metastases(From randomization to last follow-up. Analysis occurs after all patients have been on study for at least two years.)
- Local Progression(From randomization to last follow-up. Analysis occurs after all patients have been on study for at least two years.)
研究者
研究点 (54)
Loading locations...
相似试验
已完成
3 期
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract CancersStage III Distal Bile Duct Cancer AJCC v8Stage III Gallbladder Cancer AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIA Distal Bile Duct Cancer AJCC v8Stage IIIA Gallbladder Cancer AJCC v8Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIB Distal Bile Duct Cancer AJCC v8Stage IIIB Gallbladder Cancer AJCC v8Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Distal Bile Duct Cancer AJCC v8Stage IV Gallbladder Cancer AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Stage IVA Gallbladder Cancer AJCC v8Stage IVB Gallbladder Cancer AJCC v8Unresectable Extrahepatic Bile Duct CarcinomaUnresectable Gallbladder CarcinomaUnresectable Intrahepatic CholangiocarcinomaNCT03768414SWOG Cancer Research Network452
进行中（未招募）
3 期
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal CancersAdvanced Vaginal AdenocarcinomaAdvanced Vaginal Adenosquamous CarcinomaAdvanced Vaginal Squamous Cell CarcinomaCervical AdenocarcinomaCervical Adenosquamous CarcinomaStage IB2 Cervical Cancer AJCC v6 and v7Stage II Cervical Cancer AJCC v7Stage II Vaginal Cancer AJCC v6 and v7Stage IIA Cervical Cancer AJCC v7Stage IIB Cervical Cancer AJCC v6 and v7Stage III Vaginal Cancer AJCC v6 and v7Stage IIIB Cervical Cancer AJCC v6 and v7Stage IV Vaginal Cancer AJCC v6 and v7Stage IVA Cervical Cancer AJCC v6 and v7Stage IVA Vaginal Cancer AJCC v6 and v7Unresectable Vaginal CarcinomaVaginal AdenocarcinomaVaginal Adenosquamous CarcinomaVaginal CarcinomaVaginal Squamous Cell Carcinoma, Not Otherwise SpecifiedCervical Squamous Cell CarcinomaNCT02466971National Cancer Institute (NCI)450
进行中（未招募）
3 期
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerClear Cell AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaMucinous AdenocarcinomaOvarian Brenner TumorOvarian Clear Cell AdenocarcinofibromaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous AdenocarcinomaOvarian Transitional Cell CarcinomaOvarian Undifferentiated CarcinomaPrimary Peritoneal Clear Cell AdenocarcinomaPrimary Peritoneal Endometrioid AdenocarcinomaPrimary Peritoneal Serous AdenocarcinomaPrimary Peritoneal Transitional Cell CarcinomaPrimary Peritoneal Undifferentiated CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaUndifferentiated CarcinomaNCT00565851National Cancer Institute (NCI)1,052
已完成
3 期
Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00622349European Lung Cancer Working Party707
终止
3 期
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical CancerCervical AdenocarcinomaCervical Adenosquamous Cell CarcinomaStage IB Cervical CancerStage IIA Cervical CancerStage IIB Cervical CancerStage III Cervical CancerStage IVA Cervical CancerCervical Squamous Cell CarcinomaNCT00262821National Cancer Institute (NCI)402